【摘要】 目的观察用微导管(中心静脉导管)胸腔置管并胸腔内注射生物制剂和化疗药物治疗恶性胸腔积液的疗效。方法在B超定位下对64例恶性胸腔积液患者用中心静脉导管胸腔置管,放尽胸腔积液后胸腔内注入高聚生及顺铂,24小时后开放导管持续引流尽胸水及残余药物,并根据胸水引流量可重复注药;若24小时内引流液少于60ml时可拔除导管,同时可根据患者一般情况及原发肿瘤给予全身静脉化疗。结果微导管胸腔置管治疗恶性胸腔积液64例有效率93.75%,KPS评分提高20～30分。结论微导管胸腔置管治疗恶性胸腔积液胸水控制良好,患者一般行为状态明显改善;操作简单,微创安全,易于护理,不影响而能明显提高患者生活质量,值得推广。更多还原

【Abstract】 Objective To observe the efficacy of treatment of malignant hybrothorax with fine catheter(central venous catheter)and injection of biological product and chemotherapeutic agent.Methods 64 patients with malignant hydrothorax were treated with sterile central venous catheter installed in the thoracic cavity located with BUS . After the hydrothorax was drained completely, Staphylococcus Aureus Filtrate Preparation and Cisplatin were injected into thoracicavity, and the catheter was opened to drained hydrothorax and residual agents after 24 hours . The agents could be injected repeatedly until the drain was less than 60ml within 24 hours . And the patients could be administered venous chemotherapy . Results The overall response rate of the 64 patients was 93.75% , and the KPS scores or the patients were increased by 20~30 . Conclusion The malignant hydrothorax could be well controlled with the treatment of fine catheter , and the micopuncture technique was operated easily and safely , and the quality of life of patients was well improved .更多还原